{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:23:39Z","timestamp":1782570219694,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40744-020-00274-9","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T15:50:40Z","timestamp":1610207440000},"page":"347-359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dose Reduction of Tumor Necrosis Factor Inhibitor and its Effect on Medical Costs for Patients with Ankylosing Spondylitis"],"prefix":"10.1007","volume":"8","author":[{"given":"Bon San","family":"Koo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Cheol","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja-Young","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Jeong","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Sun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3542-2276","authenticated-orcid":false,"given":"Tae-Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,9]]},"reference":[{"issue":"2","key":"274_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41584-018-0155-9","volume":"15","author":"JJ O'Shea","year":"2019","unstructured":"O\u2019Shea JJ, Gadina M. Selective Janus kinase inhibitors come of age. Nat Rev Rheumatol. 2019;15(2):74\u20135.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"274_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41584-019-0188-8","volume":"15","author":"AS Schmid","year":"2019","unstructured":"Schmid AS, Neri D. Advances in antibody engineering for rheumatic diseases. Nat Rev Rheumatol. 2019;15(4):197\u2013207.","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"274_CR3","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1136\/ard.2004.035105","volume":"64","author":"JC Davis","year":"2005","unstructured":"Davis JC, van der Heijde DM, Braun J, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis. 2005;64(11):1557\u201362.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"274_CR4","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58(11):3402\u201312.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"274_CR5","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582\u201391.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"274_CR6","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136\u201346.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"274_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4078\/jrd.2020.27.1.4","volume":"27","author":"EJ Park","year":"2020","unstructured":"Park EJ, Kim H, Jung SM, Sung YK, Baek HJ, Lee J. The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean expert consensus. J Rheum Dis. 2020;27(1):4\u201321.","journal-title":"J Rheum Dis"},{"issue":"11","key":"274_CR8","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1093\/rheumatology\/kew464","volume":"56","author":"CJ Edwards","year":"2017","unstructured":"Edwards CJ, Fautrel B, Schulze-Koops H, Huizinga TWJ, Kruger K. Dosing down with biologic therapies: a systematic review and clinicians\u2019 perspective. Rheumatology (Oxford). 2017;56(11):1847\u201356.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"274_CR9","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/rheumatology\/kew033","volume":"55","author":"V Navarro-Compan","year":"2016","unstructured":"Navarro-Compan V, Plasencia-Rodriguez C, de Miguel E, et al. Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review. Rheumatology (Oxford). 2016;55(7):1188\u201394.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"274_CR10","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1002\/art.38014","volume":"65","author":"H Haibel","year":"2013","unstructured":"Haibel H, Heldmann F, Braun J, Listing J, Kupper H, Sieper J. Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare. Arthritis Rheum. 2013;65(8):2211\u20133.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"274_CR11","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1136\/annrheumdis-2011-201010","volume":"71","author":"IH Song","year":"2012","unstructured":"Song IH, Althoff CE, Haibel H, et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2-year data of the ESTHER trial. Ann Rheum Dis. 2012;71(7):1212\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"274_CR12","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71(10):1285\u201399.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"274_CR13","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","volume":"32","author":"JA Kim","year":"2017","unstructured":"Kim JA, Yoon S, Kim LY, Kim DS. Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data As A Resource For Health Research: Strengths, Limitations, Applications, And Strategies For Optimal Use Of HIRA data. J Korean Med Sci. 2017;32(5):718\u201328.","journal-title":"J Korean Med Sci"},{"key":"274_CR14","doi-asserted-by":"publisher","first-page":"e2014008","DOI":"10.4178\/epih\/e2014008","volume":"36","author":"L Kim","year":"2014","unstructured":"Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health. 2014;36:e2014008.","journal-title":"Epidemiol Health"},{"issue":"1","key":"274_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/heapol\/18.1.84","volume":"18","author":"S Kwon","year":"2003","unstructured":"Kwon S. Payment system reform for health care providers in Korea. Health Policy Plan. 2003;18(1):84\u201392.","journal-title":"Health Policy Plan"},{"issue":"5","key":"274_CR16","doi-asserted-by":"publisher","first-page":"e0124287","DOI":"10.1371\/journal.pone.0124287","volume":"10","author":"JM Seong","year":"2015","unstructured":"Seong JM, Choi NK, Shin JY, et al. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study. PLoS ONE. 2015;10(5):e0124287.","journal-title":"PLoS ONE"},{"issue":"4","key":"274_CR17","doi-asserted-by":"publisher","first-page":"322","DOI":"10.4332\/KJHPA.2014.24.4.322","volume":"24","author":"SO Bae","year":"2014","unstructured":"Bae SO, Kang GW. A comparative study of the disease codes between Korean National Health Insurance claims and Korean national hospital discharge in-depth injury survey. Health Policy Manag. 2014;24(4):322\u20139.","journal-title":"Health Policy Manag"},{"issue":"1","key":"274_CR18","doi-asserted-by":"publisher","first-page":"6736","DOI":"10.1038\/s41598-019-43155-0","volume":"9","author":"JS Park","year":"2019","unstructured":"Park JS, Jang HD, Hong JY, et al. Impact of ankylosing spondylitis on depression: a nationwide cohort study. Sci Rep. 2019;9(1):6736.","journal-title":"Sci Rep"},{"issue":"1","key":"274_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3111\/13696998.2013.856314","volume":"17","author":"AT Joyce","year":"2014","unstructured":"Joyce AT, Gandra SR, Fox KM, Smith TW, Pill MW. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naive rheumatoid arthritis patients in US health plans. J Med Econ. 2014;17(1):1\u201310.","journal-title":"J Med Econ"},{"issue":"1","key":"274_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13075-018-1772-z","volume":"21","author":"J Gratacos","year":"2019","unstructured":"Gratacos J, Pontes C, Juanola X, et al. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis. Arthritis Res Ther. 2019;21(1):11.","journal-title":"Arthritis Res Ther"},{"key":"274_CR21","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.17388","author":"JA Walsh","year":"2018","unstructured":"Walsh JA, Adejoro O, Chastek B, Palmer JB, Hur P. Treatment patterns among patients with psoriatic arthritis treated with a biologic in the united states: descriptive analyses from an administrative claims database. J Manag Care Spec Pharm. 2018. https:\/\/doi.org\/10.18553\/jmcp.2018.17388.","journal-title":"J Manag Care Spec Pharm"},{"issue":"7\u20138","key":"274_CR22","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1345\/aph.1R622","volume":"47","author":"R Halpern","year":"2013","unstructured":"Halpern R, Nadkarni A, Kalsekar I, et al. Medical costs and hospitalizations among patients with depression treated with adjunctive atypical antipsychotic therapy: an analysis of health insurance claims data. Ann Pharmacother. 2013;47(7\u20138):933\u201345.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"274_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13075-019-1943-6","volume":"21","author":"JW Park","year":"2019","unstructured":"Park JW, Kim HA, Shin K, et al. Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study. Arthritis Res Ther. 2019;21(1):163.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"274_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/annrheumdis-2014-205202","volume":"75","author":"J Zavada","year":"2016","unstructured":"Zavada J, Uher M, Sisol K, et al. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. Ann Rheum Dis. 2016;75(1):96\u2013102.","journal-title":"Ann Rheum Dis"},{"key":"274_CR25","first-page":"1","volume":"7","author":"F Cantini","year":"2013","unstructured":"Cantini F, Niccoli L, Cassara E, Kaloudi O, Nannini C. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study. Biologics. 2013;7:1\u20136.","journal-title":"Biologics"},{"issue":"7","key":"274_CR26","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.3899\/jrheum.141335","volume":"42","author":"M Yates","year":"2015","unstructured":"Yates M, Hamilton LE, Elender F, et al. Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? A Randomized Control Trial. J Rheumatol. 2015;42(7):1177\u201385.","journal-title":"J Rheumatol"},{"issue":"10","key":"274_CR27","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599\u2013613.","journal-title":"Arthritis Rheumatol."}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-020-00274-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40744-020-00274-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-020-00274-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T14:09:30Z","timestamp":1616594970000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40744-020-00274-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,9]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["274"],"URL":"https:\/\/doi.org\/10.1007\/s40744-020-00274-9","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,9]]},"assertion":[{"value":"18 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}